



NOXXON PHARMA ANNOUNCES THE IMPLEMENTATION OF A LIQUIDITY CONTRACT WITH INVEST SECURITIES

Berlin, Germany, 24 October 2016, NOXXON Pharma N.V. (Alternext Paris: ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announces that the company entrusts Invest Securities with the implementation of a liquidity contract in accordance with the Charter of Ethics established by the Association française des marchés financiers (AMAFI) of March 8, 2011 and the decision of the Autorité des Marchés Financiers (AMF) on 21 March 2011.

For the implementation of this contract, the following resources have been allocated to the liquidity account:

- €100 000 (one hundred thousand euros)
- 10 000 (ten thousand) shares

About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can be found at: www.noxxon.com